We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
-11.94%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$266M
AUM Growth
+$186M
Cap. Flow
+$212M
Cap. Flow %
79.76%
Top 10 Hldgs %
100%
Holding
10
New
2
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$134M
2
RAPP
Rapport Therapeutics
RAPP
+$86.3M

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$7.82M
2
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$12

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
1
Beam Therapeutics
BEAM
$2.64B
$128M 47.94%
+5,443,039
New +$134M
RAPP
2
Rapport Therapeutics
RAPP
$1.97B
$86.7M 32.6%
+3,728,738
New +$86.3M
ERAS icon
3
Erasca
ERAS
$6.66B
$26.1M 9.81%
11,055,554
– –
VERV
4
DELISTED
Verve Therapeutics
VERV
$9.8M 3.69%
2,008,809
– –
GOSS icon
5
Gossamer Bio
GOSS
$68.9M
$7.26M 2.73%
8,055,916
– –
QTTB icon
6
Q32 Bio
QTTB
$456M
$5.75M 2.16%
320,482
– –
UBX
7
DELISTED
Unity Biotechnology
UBX
$1.36M 0.51%
1,004,817
– –
OMIC
8
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.07M 0.4%
126,630
-1
-0% -$12
CERO
9
DELISTED
CERo Therapeutics
CERO
$432K 0.16%
722
– –
DNLI icon
10
Denali Therapeutics
DNLI
$3.7B
– –
-381,249
Closed -$7.82M

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q2 2024 Portfolio in Review

As of Q2 2024, Arch Venture Management held 10 positions worth $266M, up 231% from $80.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management deployed $212M of net new capital in Q2 2024, opening 2 new positions. Its largest new stake was Beam Therapeutics: 5,443,039 shares worth $128M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Singular Genomics Systems, Inc. Common Stock, an estimated $12 trimmed.

  • Arch Venture Management's largest Q2 2024 buy was Beam Therapeutics: 5,443,039 shares worth $128M.
  • Arch Venture Management's biggest Q2 2024 reduction was Singular Genomics Systems, Inc. Common Stock, cutting an estimated $12.
  • Arch Venture Management fully exited Denali Therapeutics in Q2 2024, selling an estimated $7.82M.
  • Arch Venture Management's ten largest holdings make up 100% of its $266M portfolio in Q2 2024.
  • Arch Venture Management opened 2 new positions and closed 1 in Q2 2024.
  • Arch Venture Management's portfolio value rose 231% quarter-over-quarter to $266M.

Based on Arch Venture Management's 13F filing for Q2 2024, filed 14 Aug 2024.